Compare CCC & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCC | CLDX |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | 2185 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | N/A | 1995 |
| Metric | CCC | CLDX |
|---|---|---|
| Price | $5.96 | $38.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $8.94 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 9.8M | 908.5K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | $10.22 | $111.39 |
| Revenue Next Year | $8.58 | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $4.08 | $19.72 |
| 52 Week High | $8.68 | $40.30 |
| Indicator | CCC | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 60.21 |
| Support Level | $5.72 | $28.51 |
| Resistance Level | $6.36 | $40.30 |
| Average True Range (ATR) | 0.31 | 1.56 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 40.47 | 78.27 |
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.